[1] Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nature reviews. Gastroenterol Hepatol, 2017, 14:122-132.
[2] WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization, 2018. https://www.who.int/hepatitis/ publications/hepatitis-c-guidelines-2018/en/.
[3] Capraru C, Feld JJ. Remaining challenges in HCV elimination. J Hepatol, 2021, 74: 964-965.
[4] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版). 中华肝脏病杂志, 2019, 27:962-979.
[5] Negro F. Residual risk of liver disease after hepatitis C virus eradication. J Hepatol. 2021, 74:952-963.
[6] Perricone G, Duvoux C, Berenguer M, et al. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. Liver Int, 2018, 38: 2170-2177.
[7] Mauss S, Buendgens L, Christensen S, et al. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C. Z Gastroenterol, 2019, 57: 139-147.
[8] Benhammou JN, Moon AM, Pisegna JR, et al. Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. Dig Dis Sci, 2020.
[9] Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: Does it matter? J Hepatol, 2012, 56 Suppl 1: S56-65.
[10] Van Der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol, 2017, 66: 485-493.
[11] Nahon P, Layese R, Bourcier V, et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology, 2018, 155: 1436-1438.
[12] Ghany MG, Morgan TR. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology, 2020, 71:686-721.
[13] Pons M, Rodriguez-Tajes S, Ignacio Esteban J, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol, 2020, 72: 472-480.
[14] El-Sherif O, Jiang ZG, Tapper EB, et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology, 2018, 154: 2111-2121.
[15] Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol, 2020, 73: 540-548.
[16] Kanwal F, Kramer JR, Asch SM, et al. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology, 2020, 71: 44-55.
[17] Georg S, Teresa B, Karin K, et al. Non-invasive risk stratification after HCV-eradication in patients with advanced chronic liver disease. Hepatology (Baltimore, Md), 2021, 73: 1275-1289. |
